Systemic Immune Activation Profiles of HIV-1 Subtype C-Infected Children and Their Mothers

Table 3

Longitudinal follow-up of a subgroup of the children.

	Baseline children; Pre-HAART; (); Median (range)	Children at 6 months; Virologically suppressive HAART; Median (range)	Children at 12 months; Virologically suppressive HAART; Median (range)
sCD14; (ng/mL)	10438; (960–18591)	7270; (889–15466)	6669; (734–13241)
β2M; (μg/mL)	4; (3–8)	2; (1.7–5)	2.5; (1.3–4.5)
hsCRP; (μg/mL)	4; (0.2–144)	1.3; (0.2–42)	1.6; (0.2–43)
MIG; (pg/mL)	5312; (1250–11245)	1441; (611–11355)	813; (385–6081)
IP10; (pg/mL)	5559; (1054–64710)	6023; (1335–18749)	4614; (997–16679)
TGF-β1; (pg/mL)	14868; (5247–30336)	13419; (39–23940)	14117; (1021–18364)
CD4^+ T cell count; (cells/μL)	854; (22–5915)	1724; (31–6401)	1731; (635–3828)
CD8^+ T cell count; (cells/μL)	1471; (181–3128)	1819; (25–5984)	1785; (44–2792)
HIV-viral load; (copies/mL blood)	2400000; (500–360000000)	25; (25–200)	25; (25–320)

HAART: highly active antiretroviral treatment.
For comparison with baseline values; .
For comparison with the 6 months’ time-point; .
sCD14 (soluble CD14), β2M (β2-microglobulin), hsCRP (high sensitivity CRP), MIG (monokine induced IFNγ), IP10 (IFNγ-inducible protein 10), and TGF-β1 (transforming growth factor beta 1).